// App-Quantinova.ai

: EMPAGLIFLOZIN REDUCES MORTALITY AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH OR WITHOUT A HISTORY OF MYOCARDIAL INFARCTION OR STROKE AT BASELINE

Researchers

Presenter

  • David H. Fitchett

Principal Investigators

  • Silvio E. Inzucchi

  • Steven Sambevski

  • Stefan Kaspers

  • Egon Pfarr

  • Jyothis T. George

  • Bernard Zinman

Medical Centers

  • St. Michael's Hosp, Toronto, ON, Canada

  • Boehringer Ingelheim Pharma GmbH, Ingelheim, Germany

Locations

  • Canada

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • BI-10773

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved